<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38318198</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2001-0370</ISSN><JournalIssue CitedMedium="Print"><Volume>24</Volume><PubDate><Year>2024</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Computational and structural biotechnology journal</Title><ISOAbbreviation>Comput Struct Biotechnol J</ISOAbbreviation></Journal><ArticleTitle>Assessing the effect of selective serotonin reuptake inhibitors in the prevention of post-acute sequelae of COVID-19.</ArticleTitle><Pagination><StartPage>115</StartPage><EndPage>125</EndPage><MedlinePgn>115-125</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.csbj.2023.12.045</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Post-acute sequelae of COVID-19 (PASC) produce significant morbidity, prompting evaluation of interventions that might lower risk. Selective serotonin reuptake inhibitors (SSRIs) potentially could modulate risk of PASC via their central, hypothesized immunomodulatory, and/or antiplatelet properties although clinical trial data are lacking.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="UNASSIGNED">This retrospective study was conducted leveraging real-world clinical data within the National COVID Cohort Collaborative (N3C) to evaluate whether SSRIs with agonist activity at the sigma-1 receptor (S1R) lower the risk of PASC, since agonism at this receptor may serve as a mechanism by which SSRIs attenuate an inflammatory response. Additionally, determine whether the potential benefit could be traced to S1R agonism. Presumed PASC was defined based on a computable PASC phenotype trained on the U09.9 ICD-10 diagnosis code.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Of the 17,908 patients identified, 1521 were exposed at baseline to a S1R agonist SSRI, 1803 to a non-S1R agonist SSRI, and 14,584 to neither. Using inverse probability weighting and Poisson regression, relative risk (RR) of PASC was assessed.A 29% reduction in the RR of PASC (0.704 [95% CI, 0.58-0.85]; P&#xa0;=&#xa0;4&#xa0;&#xd7;10<sup>-4</sup>) was seen among patients who received an S1R agonist SSRI compared to SSRI unexposed patients and a 21% reduction in the RR of PASC was seen among those receiving an SSRI without S1R agonist activity (0.79 [95% CI, 0.67 - 0.93]; P&#xa0;=&#xa0;0.005).Thus, SSRIs with and without reported agonist activity at the S1R were associated with a significant decrease in the risk of PASC.</AbstractText><CopyrightInformation>&#xa9; 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sidky</LastName><ForeName>Hythem</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansen</LastName><ForeName>Kristen A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Axle Research and Technologies, Rockville, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Girvin</LastName><ForeName>Andrew T</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Palantir Technologies, Denver, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hotaling</LastName><ForeName>Nathan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Axle Research and Technologies, Rockville, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michael</LastName><ForeName>Sam G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Palantir Technologies, Denver, CO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Axle Research and Technologies, Rockville, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gersing</LastName><ForeName>Ken</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sahner</LastName><ForeName>David K</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Axle Research and Technologies, Rockville, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>N3C consortium</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR002649</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001433</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001422</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001860</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001427</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM104942</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001420</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001439</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002243</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001445</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003096</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UM1 TR004556</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM104938</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002537</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001412</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001872</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001878</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002529</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002494</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002736</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM115516</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002369</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002541</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM115371</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002001</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002538</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM115458</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001442</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002535</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001866</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003167</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001409</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001449</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001453</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002489</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM104940</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003107</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>INV-018455</GrantID><Acronym>GATES</Acronym><Agency>Bill &amp; Melinda Gates Foundation</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003015</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002733</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 TR002306</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002003</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001876</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001436</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002378</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002384</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002553</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002389</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001414</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM104941</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002014</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002550</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002319</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001855</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001425</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002373</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002240</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002556</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003017</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001998</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001873</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001881</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002645</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001450</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002366</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM115428</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002345</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002377</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM115677</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002544</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003098</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001430</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003142</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Comput Struct Biotechnol J</MedlineTA><NlmUniqueID>101585369</NlmUniqueID><ISSNLinking>2001-0370</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>medRxiv. 2023 Feb 10:2022.11.09.22282142. doi: 10.1101/2022.11.09.22282142</RefSource><PMID Version="1">36380766</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Post-acute sequelae</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Selective serotonin reuptake inhibitors</Keyword></KeywordList><CoiStatement>The authors hereby declare no conflicting interests pertaining to the material in this manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>12</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>12</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>6</Day><Hour>3</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38318198</ArticleId><ArticleId IdType="pmc">PMC10839808</ArticleId><ArticleId IdType="doi">10.1016/j.csbj.2023.12.045</ArticleId><ArticleId IdType="pii">S2001-0370(23)00520-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Coronavirus disease (COVID-19): Post COVID-19 condition. https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-post-covid-19-condition.</Citation></Reference><Reference><Citation>Taquet M., et al. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021;18</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, Y. et al. COVID Symptoms, Symptom Clusters, and Predictors for Becoming a Long-Hauler: Looking for Clarity in the Haze of the Pandemic. 2021.03.03.21252086 Preprint at 10.1101/2021.03.03.21252086 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.03.21252086</ArticleId><ArticleId IdType="pmc">PMC9510954</ArticleId><ArticleId IdType="pubmed">36154716</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelen M., et al. Characterising long COVID: a living systematic review. BMJ Glob Health. 2021;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8478580</ArticleId><ArticleId IdType="pubmed">34580069</ArticleId></ArticleIdList></Reference><Reference><Citation>Canas, L.S. et al. Profiling post-COVID syndrome across different variants of SARS-CoV-2. 2022.07.28.22278159 Preprint at 10.1101/2022.07.28.22278159 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.07.28.22278159</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaplin S. Summary of joint guideline on the management of long COVID. Prescriber. 2021;32:33&#x2013;35.</Citation></Reference><Reference><Citation>Simon, M.A., Luginbuhl, R.D. &amp; Parker, R. Reduced Incidence of Long-COVID Symptoms Related to Administration of COVID-19 Vaccines Both Before COVID-19 Diagnosis and Up to 12 Weeks After. 2021.11.17.21263608 Preprint at 10.1101/2021.11.17.21263608 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.11.17.21263608</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuodi, P. et al. Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients tested between March 2020 and November 2021. 2022.01.05.22268800 Preprint at 10.1101/2022.01.05.22268800 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.01.05.22268800</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahase E. Covid-19: one in eight adults develops long covid symptoms, study suggests. BMJ. 2022;378:o1946.</Citation><ArticleIdList><ArticleId IdType="pubmed">35926861</ArticleId></ArticleIdList></Reference><Reference><Citation>Komaroff A.L., Lipkin W.I. Insights from myalgic encephalomyelitis/chronic fatigue syndrome may help unravel the pathogenesis of postacute COVID-19 syndrome. Trends Mol Med. 2021;27:895&#x2013;906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8180841</ArticleId><ArticleId IdType="pubmed">34175230</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul B.D., Lemle M.D., Komaroff A.L., Snyder S.H. Redox imbalance links COVID-19 and myalgic encephalomyelitis/chronic fatigue syndrome. Proc Natl Acad Sci USA. 2021;118</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8403932</ArticleId><ArticleId IdType="pubmed">34400495</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood E., Hall K.H., Tate W. Role of mitochondria, oxidative stress and the response to antioxidants in myalgic encephalomyelitis/chronic fatigue syndrome: a possible approach to SARS-CoV-2 &#x2018;long-haulers&#x2019;? Chronic Dis Transl Med. 2020;7:14&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7680046</ArticleId><ArticleId IdType="pubmed">33251031</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs J.J.L. Persistent SARS-2 infections contribute to long COVID-19. Med Hypotheses. 2021;149</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7884250</ArticleId><ArticleId IdType="pubmed">33621843</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank, Z., Senussi, Y., Alter, G. &amp; Walt, D.R. Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae. 2022.06.14.22276401 Preprint at 10.1101/2022.06.14.22276401 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.06.14.22276401</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell D.B., Laubscher G.J., Pretorius E. A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications. Biochem J. 2022;479:537&#x2013;559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8883497</ArticleId><ArticleId IdType="pubmed">35195253</ArticleId></ArticleIdList></Reference><Reference><Citation>Chertow, D. et al. SARS-CoV-2 infection and persistence throughout the human body and brain. (2021) doi:10.21203/rs.3.rs-1139035/v1.</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-1139035/v1</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung W.F., et al. COVID-19 in an immunocompromised host: persistent shedding of viable SARS-CoV-2 and emergence of multiple mutations: a case report. Int J Infect Dis. 2022;114:178&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8553657</ArticleId><ArticleId IdType="pubmed">34757008</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., et al. Prevalence and persistent shedding of fecal SARS-CoV-2 RNA in patients with COVID-19 infection: a systematic review and meta-analysis. Clin Transl Gastroenterol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8036078</ArticleId><ArticleId IdType="pubmed">33835096</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., et al. Reverse-transcribed SARS-CoV-2 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues. Proc Natl Acad Sci USA. 2021;118</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8166107</ArticleId><ArticleId IdType="pubmed">33958444</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., et al. Markers of immune activation and inflammation in individuals with postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. J Infect Dis. 2021;224:1839&#x2013;1848.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8643408</ArticleId><ArticleId IdType="pubmed">34677601</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson B.K., et al. Immune-based prediction of COVID-19 severity and chronicity decoded using machine learning. Front Immunol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8273732</ArticleId><ArticleId IdType="pubmed">34262570</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y., et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185:881&#x2013;895. e20. e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijayakumar B., et al. Immuno-proteomic profiling reveals aberrant immune cell regulation in the airways of individuals with ongoing post-COVID-19 respiratory disease. Immunity. 2022;55:542&#x2013;556. e5. e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8789571</ArticleId><ArticleId IdType="pubmed">35151371</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Rosso M.E., Palumbo M.L., Genaro A.M. Immunomodulatory effects of fluoxetine: a new potential pharmacological action for a classic antidepressant drug? Pharmacol Res. 2016;109:101&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">26644208</ArticleId></ArticleIdList></Reference><Reference><Citation>Gobin V., Van Steendam K., Denys D., Deforce D. Selective serotonin reuptake inhibitors as a novel class of immunosuppressants. Int Immunopharmacol. 2014;20:148&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">24613205</ArticleId></ArticleIdList></Reference><Reference><Citation>Sza&#x142;ach &#x141;.P., Lisowska K.A., Cuba&#x142;a W.J. The influence of antidepressants on the immune system. Arch Immunol Ther Exp] 2019;67:143&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6509093</ArticleId><ArticleId IdType="pubmed">31032529</ArticleId></ArticleIdList></Reference><Reference><Citation>Kostadinov I., et al. Study on anti-inflammatory and immunomodulatory effects of fluoxetine in rat models of inflammation. Eur J Inflamm. 2015;13:173&#x2013;182.</Citation></Reference><Reference><Citation>Taler M., et al. Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2007;17:774&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pubmed">17499975</ArticleId></ArticleIdList></Reference><Reference><Citation>Taler M., Gil-Ad I., Korob I., Weizman A. The immunomodulatory effect of the antidepressant sertraline in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. Neuroimmunomodulation. 2011;18:117&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">21088435</ArticleId></ArticleIdList></Reference><Reference><Citation>Duerschmied Daniel, Suidan Georgette L., Demers Melanie, Herr Nadine, Carbo Carla, Brill Alexander, et al. Platelet serotonin promotes the recruitment of neutrophils to sites of acute inflammation in mice. Blood. 2013;121(6):1008&#x2013;1015. doi: 10.1182/blood-2012-06-437392.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2012-06-437392</ArticleId><ArticleId IdType="pmc">PMC3567335</ArticleId><ArticleId IdType="pubmed">23243271</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong Andrea C., Devason Ashwarya S., Umana Iboro C., Cox Timothy O., Dohnalov&#xe1; Lenka, Litichevskiy Lev, et al. Serotonin reduction in post-acute sequelae of viral infection. Cell. 2023;186(22) doi: 10.1016/j.cell.2023.09.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2023.09.013</ArticleId><ArticleId IdType="pmc">PMC11227373</ArticleId><ArticleId IdType="pubmed">37848036</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto K. Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor. Eur Arch Psychiatry Clin Neurosci. 2021;271:249&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7785036</ArticleId><ArticleId IdType="pubmed">33403480</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller J.K., M&#xfc;ller W.E. Psychotropic drugs: therapeutic perspectives against Covid-19. Psychopharmakotherapie. 2021:102&#x2013;110.</Citation></Reference><Reference><Citation>Rosen D.A., et al. Modulation of the sigma-1 receptor&#x2013;IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. Sci Transl Med. 2019;11:eaau5266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6936250</ArticleId><ArticleId IdType="pubmed">30728287</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto K. Overview of the potential use of fluvoxamine for COVID-19 and long COVID. Discov Ment Health. 2023;3 doi: 10.1007/s44192-023-00036-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s44192-023-00036-3</ArticleId><ArticleId IdType="pmc">PMC10029802</ArticleId><ArticleId IdType="pubmed">36968793</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishima T., Fujita Y., Hashimoto K. Interactions of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells. Eur J Pharmacol. 2014;727:167&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">24508523</ArticleId></ArticleIdList></Reference><Reference><Citation>Strawbridge R., et al. Inflammation and clinical response to treatment in depression: a meta-analysis. J Eur Coll Neuropsychopharmacol. 2015;25:1532&#x2013;1543.</Citation><ArticleIdList><ArticleId IdType="pubmed">26169573</ArticleId></ArticleIdList></Reference><Reference><Citation>Hannestad J., DellaGioia N., Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacol Publ Am Coll Neuropsychopharmacol. 2011;36:2452&#x2013;2459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3194072</ArticleId><ArticleId IdType="pubmed">21796103</ArticleId></ArticleIdList></Reference><Reference><Citation>Song C., Halbreich U., Han C., Leonard B.E., Luo H. Imbalance between pro- and anti-inflammatory cytokines, and between Th1 and Th2 cytokines in depressed patients: the effect of electroacupuncture or fluoxetine treatment. Pharmacopsychiatry. 2009;42:182&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">19724980</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahl J., et al. The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery. Psycchoneuroendocrinology. 2014;45:77&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">24845179</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunoni A.R., et al. Cytokines plasma levels during antidepressant treatment with sertraline and transcranial direct current stimulation (tDCS): results from a factorial, randomized, controlled trial. Psychopharmacology. 2014;231:1315&#x2013;1323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4081040</ArticleId><ArticleId IdType="pubmed">24150249</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfaff E.R., et al. Identifying who has long COVID in the USA: a machine learning approach using N3C data. Lancet Digit Health. 2022;4:e532&#x2013;e541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9110014</ArticleId><ArticleId IdType="pubmed">35589549</ArticleId></ArticleIdList></Reference><Reference><Citation>St&#xfc;rmer T., Wyss R., Glynn R.J., Brookhart M.A. Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs. J Intern Med. 2014;275(6):570&#x2013;580. doi: 10.1111/joim.12197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.12197</ArticleId><ArticleId IdType="pmc">PMC4037382</ArticleId><ArticleId IdType="pubmed">24520806</ArticleId></ArticleIdList></Reference><Reference><Citation>Reis G., et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2022;10:e42&#x2013;e51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8550952</ArticleId><ArticleId IdType="pubmed">34717820</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoertel N., et al. Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study. Mol Psychiatry. 2021;26:5199&#x2013;5212.</Citation><ArticleIdList><ArticleId IdType="pubmed">33536545</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskotsky T., et al. Mortality risk among patients with COVID-19 prescribed selective serotonin reuptake inhibitor antidepressants. JAMA Netw Open. 2021;4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8593759</ArticleId><ArticleId IdType="pubmed">34779847</ArticleId></ArticleIdList></Reference><Reference><Citation>Brennan B.P., Schnabel J., Pope H.G., Hudson J.I. Antidepressant use and risk of intubation or death in hospitalized patients with COVID-19: a retrospective cohort study of clinical effectiveness. Front Psychiatry. 2022;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9520125</ArticleId><ArticleId IdType="pubmed">36186877</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenze E.J., et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA. 2020;324:2292&#x2013;2300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7662481</ArticleId><ArticleId IdType="pubmed">33180097</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante C.T., et al. Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19. New Engl J Med. 2022;387:599&#x2013;610.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9945922</ArticleId><ArticleId IdType="pubmed">36070710</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy, M.W. et al. Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial. 2022.10.17.22281178 Preprint at 10.1101/2022.10.17.22281178 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.10.17.22281178</ArticleId></ArticleIdList></Reference><Reference><Citation>Naggie, Susanna. Effect of higher-dose fluvoxamine vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19: A randomized clinical trial, 2023. https://doi.org/10.1101/2023.09.12.23295424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9857647</ArticleId><ArticleId IdType="pubmed">36633838</ArticleId></ArticleIdList></Reference><Reference><Citation>Foletto Vit&#xf3;ria Segabinazzi, da Rosa Taci&#xe9;li Fagundes, Serafin Marissa Bolson, H&#xf6;rner Rosmari. Selective serotonin reuptake inhibitor (SSRI) antidepressants reduce COVID-19 infection: prospects for use. Eur J Clin Pharmacol. 2022;78(10):1601&#x2013;1611. doi: 10.1007/s00228-022-03372-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-022-03372-5</ArticleId><ArticleId IdType="pmc">PMC9360648</ArticleId><ArticleId IdType="pubmed">35943535</ArticleId></ArticleIdList></Reference><Reference><Citation>Glebov Oleg O., Mueller Christoph, Stewart Robert, Aarsland Dag, Perera Gayan. Antidepressant drug prescription and incidence of COVID-19 in mental health outpatients: a retrospective cohort study. BMC Med. 2023;21(1) doi: 10.1186/s12916-023-02877-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-023-02877-9</ArticleId><ArticleId IdType="pmc">PMC10283271</ArticleId><ArticleId IdType="pubmed">37340474</ArticleId></ArticleIdList></Reference><Reference><Citation>Stauning Marius Ahm, G&#xfc;r Dogukan Jesper, Torp-Pedersen Christian, Tingleff Jens. Covid-19 mortality among selective serotonin reuptake inhibitor users&#x2014;results from a nationwide cohort. Clin Microbiol Infect. 2023;29(8):1075&#x2013;1082. doi: 10.1016/j.cmi.2023.04.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2023.04.028</ArticleId><ArticleId IdType="pmc">PMC10162844</ArticleId><ArticleId IdType="pubmed">37150357</ArticleId></ArticleIdList></Reference><Reference><Citation>Visos-Varela Irene, Zapata-Cachafeiro Maruxa, Pi&#xf1;eiro-Lamas Mar&#xed;a, Carracedo-Mart&#xed;nez Eduardo, Saez Marc, Herdeiro Mar&#xed;a Teresa, et al. Repurposing selective serotonin reuptake inhibitors for severity of COVID-19: a population-based study. Eur Neuropsychopharmacol. 2023;71:96&#x2013;108. doi: 10.1016/j.euroneuro.2023.03.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euroneuro.2023.03.011</ArticleId><ArticleId IdType="pmc">PMC10070770</ArticleId><ArticleId IdType="pubmed">37094487</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsiakalos Aristotelis, Ziakas Panayiotis D., Polyzou Eleni, Schinas Georgios, Akinosoglou Karolina. Early fluvoxamine reduces the risk for clinical deterioration in symptomatic outpatients with Covid-19: a real-world, retrospective, before&#x2013;after analysis. Microorganisms. 2023;11(8):2073. doi: 10.3390/microorganisms11082073.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms11082073</ArticleId><ArticleId IdType="pmc">PMC10459506</ArticleId><ArticleId IdType="pubmed">37630633</ArticleId></ArticleIdList></Reference><Reference><Citation>Rus Carla P., de Vries Bert E., de Vries Ingmar E., Nutma Idelette, Kooij J.J. Treatment of 95 post-covid patients with ssris. Sci Rep. 2023;13(1) doi: 10.1038/s41598-023-45072-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-45072-9</ArticleId><ArticleId IdType="pmc">PMC10622561</ArticleId><ArticleId IdType="pubmed">37919310</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>